Check 35,000+ stocks against 26 valuation models and 37 quality factors

CareRx Corporation (CHHHF) fair value: what the stock is really worth

As of Sep 11, 2026: fair value of CareRx Corporation $4.82, price $2.37, upside +103.4%, quality 43 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

Fair value above price? Yes
Good quality? No
Add to watchlist

Healthcare · US · ISIN CA14173C1059

Broad data Sep 24, 2026

CareRx Corporation

CHHHF · US

Cheap, value-trap riskThe stock looks deeply undervalued, but low quality raises value-trap risk.

✓Fair value $4.82 · Strongly undervalued (+103.4%)

!Quality 43/100

✓Healthy Growth (revenue 5y +17.9 %/yr)

!Thin margins · 7.2% net margin (TTM)

✓Low debt · generates free cash flow

✓2.5% dividend yield · Well covered

!Moderate moat 51/100

26 models, one by oneBear $2.87 to bull $7.50 Growth analysisrevenue history, year by year Quality 43/100 in detail37 factors, each one shown Compared with its peersrank on every measure, side by side

Watch CareRx Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range $0.0021 – $13.11 · fair‑value band $2.87 – $7.50 · the $2.37 price screens below the $4.82 fair value. Dashed = 300-day average. As of Sep 24, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

CareRx Corporation, together with its subsidiaries, provides pharmacy services to senior homes and other congregate care settings in Canada. The company also offers medication management services. It serves long-term care homes, retirement homes, assisted living facilities, and group homes. The company was formerly known as Centric Health Corporation and changed its name to CareRx Corporation in June 2020. CareRx Corporation was incorporated in 2001 and is based in Toronto, Canada.

Stock analysis

CareRx Corporation (CHHHF) currently trades at $2.37, while our model-based Fair Value estimate is $4.82, implying the stock looks roughly 50.8% undervalued today.

Valuation

Bull case: the Growth Earnings group reads highest at a median of $5.70 per share, and 18 of the 26 models we run sit above the $2.37 price.

Bear case: the Economic Profit group reads lowest at $0.7100, and 8 of the 26 models stay below the price. Evidence for this calculation is high.

Scenario range: $2.87 (bear) to $7.50 (bull), the price of $2.37 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 43/100 (below-average quality), in the Healthcare sector.

Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.

CareRx Corporation reported revenue of C$370M in FY2025 versus C$263M in FY2021, a compound +8.9%/yr. Reported net income was C$26.1M in FY2025.

Key figures

Market cap $153M · P/E ratio 7.6 · P/S ratio 0.54 · EPS (TTM) $0.3100 · Dividend yield 2.5% · Net margin 7.1% · Return on equity 27.5% · Return on assets (EBIT) 2.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 47 out of 100 (low confidence).

What moves the price

The share trades about 18% below its 52-week high and 3% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 103%, CHHHF screens cheaper than that median.

Fair Value models

Bear $2.87 Fair Value $4.82 Bull $7.50

Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($0.1890 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.

Highest evidence

FCF DCF $2.71 $4.57 $7.29 79

Growth DCF $2.65 $4.22 $6.36 78

Owner Earnings $4.49 $7.46 $11.83 75

All 26 models by family

DCF Models

FCF DCF $2.71 $4.57 $7.29 79

Owner Earnings $4.49 $7.46 $11.83 75

5Y Revenue Exit $1.64 $2.63 $3.90 72

5Y EBITDA Exit $2.72 $4.87 $7.58 73

5Y P/E Exit $3.42 $6.34 $9.72 69

10Y Revenue Exit $2.02 $3.03 $4.48 66

10Y EBITDA Exit $2.66 $4.45 $7.14 67

10Y P/E Exit $3.06 $5.38 $8.70 62

Earnings-Based

Graham-Dodd $1.96 $9.62 $13.26 64

Lynch FV $2.58 $3.69 $4.80 61

PEG = 1.0 $2.58 $3.69 $4.80 57

EPV $0.6100 $0.7100 $0.7900 74

Dividend Discount

Gordon GGM $0.1000 $0.1600 $0.2100 68

DDM Multi-Stage $0.1000 $0.1500 $0.1700 67

Multiples

P/E Multiple $4.55 $6.07 $7.58 63

P/S Multiple $3.68 $4.91 $6.14 58

P/B Multiple $3.68 $4.91 $6.14 55

EV/EBIT $1.44 $1.99 $2.55 66

EV/EBITDA $3.02 $4.10 $5.19 67

EV/Revenue $0.9600 $1.47 $1.98 53

Asset-Based

NCAV (Graham) $0.6100 $0.8100 $1.21 54

Growth DCF

Growth DCF $2.65 $4.22 $6.36 78

Rev-Margin DCF $1.64 $2.64 $3.96 72

Economic Profit

Residual Income $1.44 $1.94 $3.34 73

ROIC Compounder $0.6100 $0.7100 $0.7900 72

Growth Earnings

Growth-Adj P/E $3.99 $5.70 $7.42 67

Open the full fair value analysis →

Notify me when CHHHF reaches fair value

Put CHHHF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 43/100

Of which business quality 44 · Market factors (momentum, volatility) 29

Profitability 70

Margins and returns on capital today

Quality Growth 38

Are margins and returns improving?

Cashflow 46

Earnings quality: real cash, not paper profit

Fin. Strength 34

Balance sheet, leverage, solvency risk

Investment 68

Disciplined investing over empire-building

Low Volatility 45

Calm price path (market factor)

Momentum 23

Price trend over the last 3–12 months (market factor)

52W Momentum 19

Distance to the 52-week high (market factor)

Net Issuance 4

Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100

Revenue growth appears healthy and is supported by profitability and cash-flow quality.

Revenue growth 1 year

+0.9%

Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

−1.0%

Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+17.9%

Start year 2020 (pandemic). Over 10 years: +8.6% a year

Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.

+23.5%

’14

’15

’16

’17

’18

’19

’20

’21

’22

’23

’24

’25

Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.

−1.8% (2020) → 3.2% (2025)

Growth Forecast

Price in line with expectations

The price assumes less growth than the company has delivered so far and about what analysts expect.

What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).

+2.8%

Yearly growth needed for the next five years to justify today's price.

What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.

+4.8%

Yearly sales growth analysts expect, extended to five years.

After inflation (figures in CAD, Canada: IMF forecast 2.1% a year to 2030, 2.6% from 2016 to 2025) that is about +0.6% a year for the price and +2.6% for the forecasts.

Forecast 2026 (sales)+4.0%

Forecast 2027 (sales)+5.6%

Projected 2028 (sales)+5.2%

Projected 2029 (sales)+4.7%

Projected 2030 (sales)+4.3%

Watch CHHHF, get fair value alerts →

Compare CareRx Corporation with another stock

Price, fair value, quality and upside side by side.

First stock

Second stock

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Care Facilities · 246 stocks

Beats the industry median on 9/14 measures

Overall it ranks above its industry peers.

Valuation

Quality Score 43 · Bottom 25%

Fair Value upside +73.4% · Top 25%

Profitability

Return on equity (TTM) 27.5% · Top 25%

Return on assets 3.3% · Below median

Net margin (TTM) 7.2% · Above median

Operating margin (TTM) 3.7% · Bottom 25%

Growth and dividend

Revenue growth 4.9% · Below median

Dividend yield (TTM) 2.5% · Above median

Balance sheet

Debt / equity 0.33× · Above median

Valuation Multiplesvs Medical Care Facilities median · lower = cheaper

P/E (TTM) 7.6× · Cheapest 25%

P/B 1.34× · Cheaper than median

P/S (TTM) 0.39× · Cheapest 25%

P/FCF 6.7× · Cheaper than median

EV/EBITDA 6.7× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate.

Stock	Price	Fair Value	vs Fair Value
HCA Healthcare, Inc HCA	$431.63	$597.97	+39%
Fresenius SE FRE	€43.64	€34.49	−21%
Dr. Sulaiman Al Habib Medical Services Group 4013	225.00 SAR	109.45 SAR	−51%
Tenet Healthcare Corporation THC	$257.93	$274.35	+6%
IHH Healthcare Berhad, an investment holding company, 5225	8.03 MYR	4.87 MYR	−39%
Apollo Hospitals Enterprise Limited APOLLOHOSP	₹8,889	₹2,908	−67%
Encompass Health Corporation EHC	$123.47	$94.47	−23%
Fresenius Medical Care AG FMS	$22.27	$45.84	+106%
DaVita Inc DVA	$178.07	$215.81	+21%
Aier Eye Hospital Group 300015	¥7.91	¥10.86	+37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued High-Quality Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks Undervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark

Run the numbers yourself: free valuation calculators

DCF Calculator Graham Number Peter Lynch Formula DDM Calculator Fama-French Model Intrinsic Value

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

CareRx Corporation · Fair Value
$4.82 +51%Fair Value
Calculator →

<a href="https://www.fairvalue-calculator.com/stock/CHHHF" target="_blank" rel="nofollow noopener" style="display:inline-flex;align-items:center;gap:12px;box-sizing:border-box;font-family:system-ui,-apple-system,Segoe UI,Roboto,sans-serif;text-decoration:none;background:#0f1814;color:#eaf2ed;border:1px solid #2a3a30;border-radius:12px;padding:12px 16px;max-width:360px"><span style="line-height:1.35"><span style="font-size:12px;color:#9fb0a8">CareRx Corporation · Fair Value</span><br><b style="font-size:20px">$4.82</b> <span style="color:var(--fvc-g-mitte);font-weight:700;font-size:14px">+51%</span></span><span style="font-size:11px;color:var(--fvc-g-mitte);font-weight:700;margin-left:auto;text-align:right;line-height:1.3">Fair&nbsp;Value<br>Calculator&nbsp;→</span></a>

Cite: Fair Value Calculator (2026). "CareRx Corporation Fair Value". https://www.fairvalue-calculator.com/stock/CHHHF

Frequently asked questions

Is CareRx Corporation (CHHHF) overvalued or undervalued?

As of Sep 24, 2026, our model estimates a fair value of $4.82 versus the last price from Sep 11, 2026 of $2.37, about +103% upside (undervalued).

What is the fair value of CHHHF?

Our model-based fair value for CareRx Corporation is $4.82 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Sep 11, 2026): $2.37.

What is the quality score of CHHHF?

CareRx Corporation has a Quality Score of 43/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.

What is the price target for CareRx Corporation (CHHHF)?

Our model-based price target is the fair value of $4.82 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $2.87, optimistic scenario $7.50. It is a calculation from audited fundamentals, not an analyst target.

What is the CareRx Corporation stock forecast for 2026?

Our models put fair value at $4.82, about +103% upside versus the last price from Sep 11, 2026 of $2.37 (undervalued). Cautious scenario $2.87, optimistic scenario $7.50. The calculation is refreshed regularly with new filings.

What is the revenue of CareRx Corporation (CHHHF)?

CareRx Corporation reported trailing-twelve-month revenue of about C$375M (latest available figure, as of Sep 24, 2026).

Does CareRx Corporation pay a dividend?

CareRx Corporation currently shows a dividend yield of about 2.53% relative to its recent price (as of Sep 24, 2026).

What growth is priced into CareRx Corporation (CHHHF)?

For today's price to be fair in a discounted-cash-flow model, CareRx Corporation would have to grow free cash flow by +2.8 % per year for five years (discount rate 11.5 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +17.9 % per year. As of Sep 24, 2026.

What discount rate (WACC) does the fair value of CHHHF use?

Our models discount CareRx Corporation at 11.5 %: a base by market capitalisation (micro), damped by beta 0.62, country premium for USA. The same rate applies in all 26 models.

What is a reverse DCF?

A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For CareRx Corporation that is +2.8 % per year a year over ten years, using the same discount rate (11.5 %) and the same formula as our fair value.

How much growth has CareRx Corporation (CHHHF) delivered so far?

Over the past 5 years revenue at CareRx Corporation grew +17.9 % a year. The price currently implies +2.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.

How fast is the sector of CareRx Corporation (CHHHF) growing?

The median revenue growth in the sector is +3.0 % a year. That is the yardstick for the growth priced into CareRx Corporation (+2.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.

What is the free cash flow yield of CareRx Corporation (CHHHF)?

The free-cash-flow yield on the price is 10.07 %: that much free cash flow CareRx Corporation produces per unit of market value. When it exceeds the discount rate of our models (11.5 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.

What is the intrinsic value of CareRx Corporation (CHHHF)?

Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For CareRx Corporation it is $4.82 per share (as of Sep 24, 2026), against a price of $2.37. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).

Is CareRx Corporation stock overvalued or undervalued in 2026?

As of Sep 24, 2026, CHHHF trades below its calculated fair value: price $2.37, fair value $4.82, a gap of about +103% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.

Is fair value the same as the market price of CHHHF?

No. The price is what the market pays today ($2.37); the fair value is what the company's own numbers justify ($4.82). For CareRx Corporation the two are $2.45 per share apart. That gap is exactly why we show both numbers side by side.

How much is CareRx Corporation worth?

The market values CareRx Corporation at about $153M (market capitalisation, as of Sep 24, 2026). Per share that is $2.37; our models calculate a fair value of $4.82 per share.

What do the bullish and bearish scenarios say about CHHHF?

Our models span a range for CareRx Corporation: cautious scenario $2.87, base $4.82, optimistic $7.50 per share (as of Sep 24, 2026, price $2.37). The range comes from different growth and margin assumptions, not from analyst opinions.

What is the P/E ratio of CHHHF?

CareRx Corporation trades at a price-to-earnings ratio of 7.6 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $4.82 is built from several models across several years. Other multiples: P/B 1.3, P/S 0.4, EV/EBITDA 6.7.

How solid is the balance sheet of CareRx Corporation (CHHHF)?

Balance-sheet figures for CareRx Corporation (as of Sep 24, 2026): return on equity 27.5%, debt of 0.33 per unit of equity. They feed the Quality Score of 43/100, which measures business quality independently of the share price.

How far is CHHHF from its 52-week high?

CareRx Corporation trades at $2.37, about 18% below its 52-week high of $2.89 and 3% above the low of $2.31 (as of Sep 11, 2026). Distance from the high says nothing about value: that is what the fair value of $4.82 is for.

Which stocks are comparable to CareRx Corporation?

From the same area (Healthcare) we also value HCA Healthcare, Inc, Fresenius SE, Dr. Sulaiman Al Habib Medical Services Group, Tenet Healthcare Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.

Is CareRx Corporation stock attractive at the current price?

The data as of Sep 24, 2026: price $2.37, calculated fair value $4.82 (+103%), Quality Score 43/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.

How is the fair value of CHHHF calculated?

We run CareRx Corporation through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $4.82, with the spread shown as a cautious and an optimistic scenario.

Is it still worth investing in stocks now?

The global stock market currently sits 14.5 % above its aggregate fair value. CareRx Corporation currently trades 51 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.

What is the share price of CareRx Corporation (CHHHF)?

The latest price we hold is from Sep 11, 2026 and stands at $2.37. Our model-based fair value is $4.82, about +103% upside (undervalued). We carry closing prices from our data provider, not a live tick.

What should I pay attention to with CareRx Corporation right now?

The large discount to fair value meets weak quality (43/100). That raises the risk this is a value trap rather than a bargain. The price is below even our cautious bear case ($2.87). The market is more pessimistic than our downside scenario. The model range is unusually wide ($2.87 to $7.50). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of CareRx Corporation

How large is the market capitalisation of CareRx Corporation (CHHHF)?

The market capitalisation of CareRx Corporation is $153M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.

What is the P/S ratio of CareRx Corporation (CHHHF)?

The price-to-sales ratio of CareRx Corporation is 0.54 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.

What are the earnings per share of CareRx Corporation (CHHHF)?

Earnings per share at CareRx Corporation are $0.3100 (price ÷ EPS = P/E 7.6). Earnings per share over the last twelve months: total profit spread across every single share.

What is the dividend yield of CareRx Corporation (CHHHF)?

The dividend yield of CareRx Corporation is 2.5% (payout 19.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.

What is the net margin of CareRx Corporation (CHHHF)?

The net margin of CareRx Corporation is 7.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.

What is the return on equity of CareRx Corporation (CHHHF)?

The return on equity (ROE) of CareRx Corporation is 27.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.

What is the EBIT return on assets of CareRx Corporation (CHHHF)?

On an EBIT basis the return on assets of CareRx Corporation is 2.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.

What is the operating margin of CareRx Corporation (CHHHF)?

The operating margin of CareRx Corporation is 3.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.

How fast is revenue growing at CareRx Corporation (CHHHF)?

Revenue at CareRx Corporation is growing +4.9% versus a year earlier (3y avg −1.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.

How fast are earnings growing at CareRx Corporation (CHHHF)?

Earnings per share at CareRx Corporation are growing +426% versus a year earlier. How much earnings per share grew versus a year earlier.

How much net debt does CareRx Corporation (CHHHF) carry?

The net debt of CareRx Corporation is C$63.5M (fiscal year 2025, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.

Free · no account needed

Watch CareRx Corporation in the live analysis

One click puts CareRx Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.